Assessment of HyperQ Signal for Detecting Ischemia During Dobutamine Stress ECG
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of the study is to verify the ability of the HyperQ signal to detect Dobutamine induced Ischemia. The gold standard for ischemia will be the results of Angiography if performed, or Echocardiographic imaging, which was performed during the test.
| Condition | Intervention | Phase |
|---|---|---|
|
Myocardial Ischemia |
Device: HyperQ Signal recording |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Diagnostic |
| Official Title: | An Assessment of the HyperQ Signal for Detecting Ischemia During Dobutamine Stress Echocardiography (DSE) |
- HyperQ Signal recorded during the DES Test
- DES Outcome/ Angiography
| Estimated Enrollment: | 150 |
| Study Start Date: | March 2006 |
| Estimated Study Completion Date: | February 2007 |
Subjects referred for Dobutamine Stress Echocardiography who will sign an Informed consent form will go through the test. High resolution ECG from 12 leads will be recorded using BSP's HyperQ system before, during and following the Echo testing. This wil be done without interfering or affecting any aspect of the normal procedure. Standard Protocol will be used with standard test termination indications.
The Diagnostic stage will include analysis of the hyperQ signal, aiming to classify results as ischemic or non-ischemic.
The HyperQ data will be compared to DSE results which will be used as the "gold standard" for this study unless Angiography results are obtained.
An additional comparison evaluation will be performed to assess the advantage of the HyperQ results on the ST-changes results obtained from conventional ECG.In addition all recruited subjects will be followed for up to 12 months.During this period a phone call will be performed every 3 months to evaluate cardiac status, hospitalization and especially Angiography procedures.
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Subject referred to dobutamine stress Echocardiography
- Subject signed informed consent
Exclusion Criteria:
- Subjects with implantable Pacemakers or Defibrillators
- Subjects with Wolff-Parkinson-White Syndrome
Contacts and Locations| Contact: David Rosenman, MD | +972-50-8685923 | |
| Contact: Nechi Almogy, MD | +972-54-6602697 | nechi@bsp.co.il |
| Israel | |
| Cardiology Department, Shaarey Zedek Hospital | Recruiting |
| Jerusalem, Israel | |
| Principal Investigator: | David Rosenmann, MD | Shaarey Zedek Hospital, Jerusalem, Israel |
More Information
Additional Information:
No publications provided
| ClinicalTrials.gov Identifier: | NCT00310622 History of Changes |
| Other Study ID Numbers: | SHZ01 |
| Study First Received: | April 2, 2006 |
| Last Updated: | February 28, 2007 |
| Health Authority: | Israel: Ethics Commission |
Keywords provided by BSP Biological Signal Processing Ltd.:
|
HyperQ Ischemia dobutamine |
Additional relevant MeSH terms:
|
Myocardial Ischemia Coronary Artery Disease Ischemia Heart Diseases Cardiovascular Diseases Vascular Diseases Coronary Disease Arteriosclerosis Arterial Occlusive Diseases Pathologic Processes Dobutamine Cardiotonic Agents Cardiovascular Agents |
Therapeutic Uses Pharmacologic Actions Sympathomimetics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Adrenergic beta-1 Receptor Agonists Adrenergic beta-Agonists Adrenergic Agonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Protective Agents |
ClinicalTrials.gov processed this record on May 16, 2013